---
id: 053
title: Linezolid Side Effects (Myelosuppression and Serotonin Syndrome)
category: antimicrobials
subcategory: oxazolidinones
tags: [linezolid, myelosuppression, thrombocytopenia, serotonin-syndrome, MAOI, neuropathy]
difficulty: hard
---

## Question

What are the major **toxicities** of linezolid, and when do they occur? Use the **"LINEZOLID toxicity = MAN DOWN"** mnemonic.

## Answer

### **"LINEZOLID toxicity = MAN DOWN" Mnemonic:**

**MAN DOWN:**
- **M**yelosuppression (thrombocytopenia, anemia)
- **A**t risk after >10-14 days therapy
- **N**europathy (peripheral, optic) after >28 days

**DOWN:**
- **D**uration-dependent toxicity
- **O**ptic neuropathy (irreversible)
- **W**eekly CBC monitoring required
- **N**o SSRIs (serotonin syndrome risk)

### **Major Toxicities:**

#### **1. Myelosuppression (Most Common):**

| Type | Frequency | Time to Onset | Reversibility |
|------|-----------|---------------|---------------|
| **Thrombocytopenia** | 3-10% | 10-14 days | **Reversible** (7-14 days after D/C) |
| **Anemia** | 2-5% | 10-14 days | Reversible |
| **Leukopenia** | 1-3% | 10-14 days | Reversible |

**Risk Factors for Myelosuppression:**
- **Duration >10-14 days** (strongest predictor)
- Renal impairment (CrCl <30 mL/min)
- Baseline thrombocytopenia (<150,000)
- Concurrent myelosuppressive drugs

**Monitoring:**
- **Baseline CBC** before starting
- **Weekly CBC** if treatment >2 weeks
- Consider discontinuing if platelets <75,000 or symptomatic

#### **2. Serotonin Syndrome (Rare but Serious):**

**Mechanism:** Linezolid is a **weak, reversible MAO-A inhibitor** → ↑ serotonin if combined with serotonergic agents

**Risk with Concomitant Serotonergic Agents:**

| Drug Class | Examples | Risk Level |
|------------|----------|------------|
| **SSRIs** | Fluoxetine, sertraline, citalopram | Moderate |
| **SNRIs** | Venlafaxine, duloxetine | Moderate |
| **TCAs** | Amitriptyline | Low-Moderate |
| **MAOIs** | Phenelzine, selegiline | **HIGH (contraindicated)** |
| **Other** | Tramadol, meperidine, dextromethorphan | Moderate |

**2022 JAMA Study:** Concurrent antidepressants did NOT significantly increase risk (absolute risk <1%)

**2023 Meta-Analysis:** **Multiple serotonergic agents** (≥2) + linezolid → OR 5.18 for serotonin syndrome

**Clinical Presentation:**
- Altered mental status, agitation
- Hyperthermia, diaphoresis
- Tremor, hyperreflexia, clonus
- Autonomic instability

**FDA Guidance:**
- If linezolid necessary: **Stop SSRI/SNRI** and monitor for 2 weeks (5 weeks if fluoxetine)
- Alternative: Use tedizolid (lower MAOI effect) or non-serotonergic antidepressant

#### **3. Peripheral and Optic Neuropathy (Long-Term):**

**Peripheral Neuropathy:**
- **Onset:** After >28 days therapy
- **Presentation:** Paresthesias, pain, numbness (stocking-glove)
- **Reversibility:** Variable (may be **irreversible**)

**Optic Neuropathy:**
- **Onset:** After >28 days (can be weeks to months)
- **Presentation:** Vision loss, decreased color vision, scotomas
- **Reversibility:** Usually **irreversible**
- **Monitoring:** Monthly ophthalmologic exams if treatment >3 months

**Mechanism:** Inhibition of mitochondrial protein synthesis

## Key Points

### **Other Side Effects:**

| Side Effect | Frequency | Notes |
|-------------|-----------|-------|
| **Lactic acidosis** | Rare | Mitochondrial toxicity |
| **Nausea/diarrhea** | 5-10% | Usually mild |
| **Headache** | 2-5% | Usually mild |
| **Elevated LFTs** | 1-2% | Monitor in liver disease |

### **Clinical Pearls:**
- **Limit duration to <28 days** when possible (reduces neuropathy risk)
- **Weekly CBC** essential for courses >14 days
- **Myelosuppression is REVERSIBLE** (recovers 7-14 days after stopping)
- **Optic neuropathy may be IRREVERSIBLE** (limit long-term use)
- **Serotonin syndrome risk LOW** with single SSRI (but higher with multiple agents)

### **When to Discontinue Linezolid:**
- Platelets <75,000/µL or symptomatic thrombocytopenia
- Visual symptoms (blurred vision, color vision changes)
- Peripheral neuropathy symptoms
- Severe lactic acidosis (pH <7.25, lactate >4 mmol/L)

### **Drug Selection:**
- If prolonged therapy (>2 weeks) needed: Consider **tedizolid** (lower myelosuppression risk)
- If patient on SSRIs: Consider tedizolid or discontinue SSRI

## Sources

- [StatPearls NBK539793: Linezolid]
- [PMC7654556: Reversible Myelosuppression with Linezolid]
- [ACP 2024: Linezolid-Induced Myelosuppression]
- [JAMA Network Open 2022: Linezolid and Antidepressants]
- [FDA Drug Safety Communication: Linezolid-Serotonergic Drug Interaction]

## Media

N/A
